Recently, such delivery systems have been used in ongoing clinical trials involving subretinal administration of AAV-SaCas9/multiplexed sgRNAs to delete a disease-causing mutation in the CEP290 gene in patients suffering from Leber’s congenital amaurosis type 10 (LCA10)110 (Table S1). Here, CEP290 is linked to Leber congenital amaurosis 10.